Bristol-myers Squibb Drug Patent Portfolio
Bristol-myers Squibb owns 1 orange book drug protected by 5 US patents Given below is the list of Bristol-myers Squibb's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8629171 | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | 13 Jun, 2031 | Active |
| US8329159 | Hepatitis C virus inhibitors | 24 Jul, 2029 | Active |
| US8642025 | Hepatitis C virus inhibitors | 11 Aug, 2027 | Active |
| US8900566 | Hepatitis C virus inhibitors | 08 Aug, 2027 | Active |
| US9421192 | Hepatitis C virus inhibitors | 08 Aug, 2027 | Active |
Latest Legal Activities on Bristol-myers Squibb's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bristol-myers Squibb.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 09 Jan, 2023 | US8900566 |
|
Maintenance Fee Reminder Mailed
Critical
| 25 Jul, 2022 | US8900566 |
|
Expire Patent
Critical
| 14 Mar, 2022 | US8642025 |
|
Maintenance Fee Reminder Mailed
Critical
| 27 Sep, 2021 | US8642025 |
|
Expire Patent
Critical
| 18 Jan, 2021 | US8329159 |
|
Expire Patent
Critical
| 28 Sep, 2020 | US9421192 |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Aug, 2020 | US8329159 |
|
Maintenance Fee Reminder Mailed
Critical
| 13 Apr, 2020 | US9421192 |
|
Patent Term Extension Certificate
Critical
| 17 Dec, 2019 | US8329159 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Nov, 2019 | US8329159 |
|
Email Notification
Critical
| 12 Nov, 2019 | US8329159 |
|
Correspondence Address Change
Critical
| 08 Nov, 2019 | US8329159 |
|
Email Notification
Critical
| 11 Oct, 2019 | US8642025 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 11 Oct, 2019 | US8642025 |
|
Correspondence Address Change
Critical
| 10 Oct, 2019 | US8642025 |
Bristol-myers Squibb's Drug Patent Litigations
Bristol-myers Squibb's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 23, 2010, against patent number US8329159. The petitioner , challenged the validity of this patent, with Makonen Belema et al as the respondent. Click below to track the latest information on how companies are challenging Bristol-myers Squibb's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8329159 | August, 2010 |
Decision
(31 Jan, 2011)
| Makonen Belema et al | |
Bristol-myers Squibb's Family Patents
Bristol-myers Squibb Drug List
Given below is the complete list of Bristol-myers Squibb's drugs and the patents protecting them.
1. Daklinza
Daklinza is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8629171 | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
13 Jun, 2031
(6 years from now)
| Active |
| US8329159 | Hepatitis C virus inhibitors |
24 Jul, 2029
(4 years from now)
| Active |
| US8642025 | Hepatitis C virus inhibitors |
11 Aug, 2027
(2 years from now)
| Active |
| US8900566 | Hepatitis C virus inhibitors |
08 Aug, 2027
(2 years from now)
| Active |
| US9421192 | Hepatitis C virus inhibitors |
08 Aug, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daklinza's drug page